Journal Scans
Single Agent Carboplatin Versus Carboplatin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer: Final Survival Results of a SWOG (S0200) Phase 3 Randomized Trial
No Hypersensitivity With Carboplatin + PLD for Ovarian Cancer
M Markman, J Moon, S Wilczynski, AM Lopez, KM Rowland Jr, DP Michelin, VJ Lanzotti, GL Anderson, DS Alberts
20091130
2009 Dec 30
Gynecol Oncol
Single Agent Carboplatin Versus Carboplatin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer: Final Survival Results of a SWOG (S0200) Phase 3 Randomized Trial
Gynecol Oncol. 2009 Dec 30;[Online Ahead of Print], M Markman, J Moon, S Wilczynski, AM Lopez, KM Rowland Jr, DP Michelin, VJ Lanzotti, GL Anderson, DS Alberts
TAKE-HOME MESSAGE
Abstract
Abstract
Objectives: Randomized phase 3 trials have demonstrated the utility of a regimen of carboplatin plus pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer, and have provided provocative data suggesting a substantially lower risk of carboplatin-associated hypersensitivity if PDL is delivered in combination with the platinum agent. Methods: To further examine both of these clinically-relevant issues, the survival outcome (with longer follow-up) and hypersensitivity reaction profile of...
